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Introduction 
Anti-aminoacyl t-RNA antibodies (anti-Jol, PL-7, PL-12, 
EJ, OJ and KJ) are evident in over a quarter of patients 
with polymyositis, dermatomyositis or idiopathic inflam- 
matory myositis (1). Over two thirds of such patients have 
interstitial lung disease (ILD) (1). The anti-synthetase anti- 
body (ASA) syndrome comprises various combinations of 
ILD, fever, inflammatory myositis, symmetric inflamma- 
tory arthritis, Raynauds phenomenon (RP) and mechanics 
hands (2,3). These may occur in any temporal sequence and 
some features may be more prominent than others. Myo- 
sitis is evident in the majority of patients. However, disease 
prognosis is determined by the severity and rate of progres- 
sion of the ILD (3). Pulmonary histology generally confirms 
an interstitial fibro-inflammatory process (4). While respir- 
atory symptoms often develop over many weeks occasional 
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patients have presented with rapidly progressive lung dis- 
ease or the adult respiratory distress syndrome (1). Among 
these latter patients some have had little obvious myositis 
(1). We describe a patient with a fatal respiratory illness of 
rapid onset in whom anti-Jo antibodies were associated 
with a pulmonary vasculitis but no overt myositis. 
Case Report 
A previously well 60-year-old Caucasian female presented 
with pleuritic chest pain and a 2 week history of progressive 
dyspnoea, fever, non-productive cough and arthralgia of 
the hands and feet. She denied recent overseas travel and 
occupational exposure to allergens or toxic substances. Her 
past medical history included hypertension, mild episodic 
asthma and hypothyroidism. There was no significant fam- 
ily history and the patient was a non-smoker. Her medica- 
tions were thyroxine, frusemide and atenolol and inhaled 
salbutamol, ipratropium bromide and betamethasone. 
On examination she was pyrexial (38”C), hypotensive 
(blood pressure 100165) and hypoxaemic (0, saturation 
92% on 28% mask oxygen). Bibasal inspiratory crackles 
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Discussion 
PLATE 1. Necrotizing vasculitis of medium sized 
pulmonary artery. (Original magnification x 250.) 
Martins scarlet blue stain used. 
without wheezes were evident in the chest and the chest 
X-ray confirmed bibasal alveolar shadowing. Blood tests 
confirmed a haemoglobin of 12.7 g dl - I, white cell count of 
17.2 x lo9 l- i (90% neutrophils), platelets 506 x lOI* l- ‘, 
erythrocyte sedimentation rate 98 mm h - ‘. Serum electro- 
lytes, blood glucose and creatine kinase were normal. The 
ECG showed only a sinus tachycardia. 
Despite treatment with broad spectrum antibiotics and 
inotropes she developed acute respiratory failure requiring 
mechanical ventilation. Sputum, blood, bronchoalveolar 
fluid and urine cultures were all negative as indeed were 
serological tests for HIV 1 and 2, respiratory syncytial 
virus, equine morbillivirus, Legionella and Mycoplasma. 
Serum IgM for CMV and rheumatoid factor were also 
negative as were anti-neutrophil cytoplasmic (OrgenTec, 
D-551 16 Mainz, Germany), anti-GBM (Eurodiagnostica, 
20061 Malmii, Sweden), antinuclear (ANA) (Sanofi 
Diagnostics Pasteur Inc, MN, U.S.A.) and anti-dsDNA 
antibodies (Ortho-Clinical Diagnostics, Amersham, U.K.). 
Antibodies to the Jo-l antigen were detected by ELISA 
(OrgenTec, D-551 16 Mainz, Germany) on two separate 
occasions separated by 13 days; optical density of patient’s 
sera 0.512 and 0.687, respectively, with a mean cut-off for 
positive sera of 0.28. However, owing to the rapid onset of 
the patient’s illness and the possibility of nosocomial infec- 
tion, steroid immunosuppression for ILD was delayed until 
day 10. In spite of this, the patient developed progressive 
multiorgan failure and died 30 days after admission. 
Postmortem examination confirmed an acute subendo- 
cardial infarction. The lungs showed diffuse alveolar 
damage. Many medium sized pulmonary arteries showed 
necrotizing vasculitis (Plate 1). Eosinophils were not 
observed in the inflammatory infiltrate. Some of these 
necrotic vessels were associated with parenchymal infarc- 
tion. There was no evidence of interstitial fibrosis. Grocott, 
PAS, ZN and Gram-stain were negative. No viral inclu- 
sions were seen. Postmortem viral cultures of the lung 
were negative and electron microscopy did not reveal any 
pathogen. Vasculitis was not identified in the skin, kidneys, 
liver, spleen, heart, brain and pancreas. Skeletal muscles 
showed no myositis. Hashimotos thyroiditis was present. 
The anti-Jo-l antibody is the commonest of the anti- 
aminoacyl tRNA synthetase antibodies. It reacts with, and 
specifically inhibits, histadyl transfer RNA synthetase (5). 
The ASA syndrome is most commonly accompanied by 
myositis (94%) ILD (72%) arthritis (56%) and RP (68%) 
(3). In our patient, fever, arthralgia and ILD occurred in 
isolation of clinical, biochemical and histological myositis 
and without mechanics hands or RP. Friedman et al. (1) 
have recently reported 10 patients with anti-aminoacyl 
t-RNA antibodies and ILD but no overt myositis despite a 
median follow-up of 3.5 years (range 0.04-13.5 years). In 
contrast, Imokawa et al. (6) reported polymyositis 4 
months after a patient’s initial presentation with bronchio- 
litis obliterans organizing pneumonia and anti-Jo-l anti- 
bodies. Thus, myositis and perhaps other manifestations of 
the ASA syndrome may have developed later in our patient 
had she survived her respiratory disease. 
Two previous reports document vascultis of small and 
medium sized muscular pulmonary arteries in patients with 
polymyositis (7,s). In both reports usual interstitial pneu- 
monitis or ILD was also observed (7,8). To our knowledge 
there have been no previous reports of pulmonary vascu- 
litis associated with anti-Jo-l antibodies in the absence 
of polymyositis and other lung pathology. In general, 
transbronchial lung biopsies from patients with anti-Jo-l 
antibodies have shown interstitial fibrosis, chronic 
inflammatory cell infiltrates or alveolitis (1,4,9). These 
features were specifically absent in our patient. While the 
pathogenetic significance of the anti-Jo-l antibodies in our 
patient is unclear, other causes of pulmonary vasculitis such 
as Behcets syndrome were excluded on the basis of the 
patient’s history and examination. 
Rapid progression of pulmonary disease is uncommon in 
the ASA syndrome and was evident in only two of the 10 
patients reported by Friedman et al. (1). In our patient the 
rapid progression of the pulmonary disease was most likely 
due to the widespread pulmonary vasculitis. We suggest 
that patients with acute progressive dyspnoea associated 
with arthralgia, muscle aches and RP should be assessed for 
antisynthetase antibodies. A negative test for ANA does 
not exclude the ASA syndrome (10) as the target antigen is 
predominantly cytoplasmic in location. 
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